Patients with advanced ovarian cancer (FIGO stage III C) and highly disseminated tumor will
be randomized into two arms: primary debulking surgery followed by adjuvant chemotherapy vs.
neoadjuvant chemotherapy followed by interval debulking surgery (IDS). The primary end point
is the evaluation and comparison of the surgical complications of primary surgery and IDS and
the evaluation of the progression free survival (PFS)